Estrella Immunopharma, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q3 2021 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Estrella Immunopharma, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q3 2021 to Q2 2024.
  • Estrella Immunopharma, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending June 30, 2024 was $4.48M, a 75% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $4.48M +$1.92M +75% Jun 30, 2024 10-K 2024-09-27
Q2 2023 $2.56M +$2.4M +1528% Jun 30, 2023 10-K 2024-09-27
Q1 2023 $318K +$234K +276% Mar 31, 2023 10-Q 2023-05-18
Q4 2022 $292K +$240K +462% Dec 31, 2022 10-Q 2023-08-01
Q3 2022 $230K +$206K +877% Sep 30, 2022 10-Q 2022-11-14
Q2 2022 $157K Jun 30, 2022 10-Q 2022-08-08
Q1 2022 $84.7K Mar 31, 2022 10-Q 2022-05-16
Q4 2021 $52K Dec 31, 2021 10-K 2023-03-14
Q3 2021 $23.5K Sep 30, 2021 10-Q 2021-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.